Department of Medicine, Leon H. Charney Division of Cardiology, New York University School of Medicine, New York, NY, USA.
Arterioscler Thromb Vasc Biol. 2011 Nov;31(11):2378-82. doi: 10.1161/ATVBAHA.111.226688.
Although the roles of the sterol response element binding protein-1 (SREBP1) and SREBP2 transcription factors in regulating fatty acid and cholesterol synthesis and uptake have been known for some time, it was recently discovered that 2 related microRNAs (miRs), miR-33a and miR-33b, are embedded in these genes. Studies indicate that miR-33a and miR-33b act with their host genes, Srebp2 and Srebp1, respectively, to reciprocally regulate cholesterol homeostasis and fatty acid metabolism in a negative feedback loop. miR-33 has been shown to posttranscriptionally repress key genes involved in cellular cholesterol export and high-density lipoprotein metabolism (Abca1, Abcg1, Npc1), fatty acid oxidation (Crot, Cpt1a, Hadhb, Ampk), and glucose metabolism (Sirt6, Irs2). Delivery of inhibitors of miR-33 in vitro and in vivo relieves repression of these genes, resulting in upregulation of the associated metabolic pathways. In mouse models, miR-33 antagonism has proven to be an effective strategy for increasing plasma high-density lipoprotein cholesterol and fatty acid oxidation and protecting from atherosclerosis. These exciting findings have opened up promising new avenues for the development of therapeutics to treat dyslipidemia and other metabolic disorders.
虽然固醇调节元件结合蛋白-1(SREBP1)和 SREBP2 转录因子在调节脂肪酸和胆固醇合成和摄取方面的作用已经为人所知一段时间了,但最近发现 2 种相关的 microRNA(miRs),miR-33a 和 miR-33b,嵌入这些基因中。研究表明,miR-33a 和 miR-33b 与其宿主基因 Srebp2 和 Srebp1 分别作用,以负反馈回路相互调节胆固醇稳态和脂肪酸代谢。miR-33 已被证明可在后转录水平抑制细胞胆固醇外排和高密度脂蛋白代谢(Abca1、Abcg1、Npc1)、脂肪酸氧化(Crot、Cpt1a、Hadhb、Ampk)和葡萄糖代谢(Sirt6、Irs2)的关键基因。体外和体内递送 miR-33 的抑制剂可解除对这些基因的抑制,从而上调相关代谢途径。在小鼠模型中,miR-33 拮抗已被证明是增加血浆高密度脂蛋白胆固醇和脂肪酸氧化并预防动脉粥样硬化的有效策略。这些令人兴奋的发现为开发治疗血脂异常和其他代谢紊乱的疗法开辟了有希望的新途径。